NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC announce that KSF has commenced an investigation into Impax Laboratories Inc. (Nasdaq: IPXL).
Shares of Impax Labs was halted in aftermarket trading following Company’s announcement that the Food and Drug Administration issued a new Form 483 with twelve (12) observations, three (3) of which are designated as repeat observations from inspections that occurred prior to the Warning Letter. According to the Company, until remedial action is complete and the FDA has confirmed compliance with current Good Manufacturing Procedures, approval of pending and new applications listing the Hayward facility as a manufacturing location of finished dosage forms may be withheld.
KSF’s investigation is focusing on whether Impax Labs and/or its officers and directors violated state or federal securities laws.
If you have information that would assist KSF in its investigation, or would like to discuss your legal rights, you may, without obligation or cost to you, e-mail or call KSF Managing Partner, Lewis Kahn (firstname.lastname@example.org), toll free, 877-515-1850, or via cell phone any time at 504-301-7900.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities class action and shareholder derivative litigation with offices in New York and Louisiana. KSF's lawyers have significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders.
To learn more about KSF, you may visit www.ksfcounsel.com.